Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA: Omalizumab Re-treatment and Step-up in CSU
NCT02161562Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of omalizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Aug 2014; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT02161562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161562.